1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 22, 04/Jun/2026
  4. Article
Research Open Access
Like 0
Download

SDG 3: STI

Abstract

BACKGROUND

From 1 March 2020, the Centre for Sexual Health Amsterdam limits presumptive treatment for chlamydia or gonorrhoea to clients notified by steady partners. Treatment after notification by non-steady partners requires a positive test result.

AIM

We aimed to evaluate this change in policy on unnecessary antibiotic treatment, time to treatment and lost to follow-up clients.

METHODS

We included consultations (with testing) following partner notification for chlamydia or gonorrhoea between 1 March 2017 and 1 March 2023. Primary outcome was unnecessary antibiotic treatment (presumptive treatment with negative test result) before vs after the policy change. We also assessed return for treatment of confirmed and not presumptively treated individuals after the policy change.

RESULTS

From 4,579 consultations, unnecessary antibiotics were prescribed for 786/1,318 (59.6%) clients for chlamydia and 729/1,117 (65.3%) clients for gonorrhoea before 1 March 2020. After 1 March 2020, this decreased to 324/1,275 (25%) and 341/1,369 (25%), respectively, corresponding to a relative reduction of 58% for chlamydia (adjusted relative risk (aRR): 0.42; 95% confidence interval (CI): 0.37–0.47) and 63% (aRR: 0.37; 95% CI: 0.33–0.42) for gonorrhoea. After the policy change, clients not given presumptive treatment but later diagnosed returned after a median of 7 days (interquartile range (IQR): 5–8) for chlamydia and 6 days (IQR: 4–7) for gonorrhoea. Missed treatment occurred in 4/155 (2.6%) of chlamydia and 5/158 (3.2%) of gonorrhoea consultations.

CONCLUSION

The new partner management protocol substantially reduced unnecessary antibiotic treatment for chlamydia and gonorrhoea. The majority of confirmed infections still received appropriate treatment.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.22.2500754
2026-06-04
2026-07-18
/content/10.2807/1560-7917.ES.2026.31.22.2500754
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/22/eurosurv-31-22-5.html?itemId=/content/10.2807/1560-7917.ES.2026.31.22.2500754&mimeType=html&fmt=ahah

References

  1. Keizer K, Götz H. Soa- en hiv-partnermanagement. LCI-draaiboek. [STI and HIV Partner Management. LCI Handbook]. Amsterdam: National Institute for Public Health and the Environment (RIVM); 2024. Dutch. Available from: https://lci.rivm.nl/draaiboeken/partnermanagement
  2. Wong D, Berman SM, Furness BW, Gunn RA, Taylor M, Peterman TA. Time to treatment for women with chlamydial or gonococcal infections: a comparative evaluation of sexually transmitted disease clinics in 3 US cities. Sex Transm Dis. 2005;32(3):194-8.  https://doi.org/10.1097/01.olq.0000154494.95138.70  PMID: 15729159 
  3. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis. 1997;24(4):181-4.  https://doi.org/10.1097/00007435-199704000-00001  PMID: 9101628 
  4. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352(7):676-85.  https://doi.org/10.1056/NEJMoa041681  PMID: 15716561 
  5. Golden MR, Kerani RP, Stenger M, Hughes JP, Aubin M, Malinski C, et al. Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT. PLoS Med. 2015;12(1):e1001777.  https://doi.org/10.1371/journal.pmed.1001777  PMID: 25590331 
  6. Tang KWK, Millar BC, Moore JE. Antimicrobial Resistance (AMR). Br J Biomed Sci. 2023;80:11387.  https://doi.org/10.3389/bjbs.2023.11387  PMID: 37448857 
  7. Baran A, Kwiatkowska A, Potocki L. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race. Int J Mol Sci. 2023;24(6):5777.  https://doi.org/10.3390/ijms24065777  PMID: 36982857 
  8. Kong FY, Hocking JS. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infect Dis. 2015;15(1):293.  https://doi.org/10.1186/s12879-015-1030-9  PMID: 26220080 
  9. European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in the European Union/European Economic Area, 2022. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/gonococcal-antimicrobial-susceptibility-surveillance-europe.pdf
  10. Kayaert L, Sarink D, Visser M, Willemstein I, Alexiou Z, van Bergen I, et al. Seksueel overdraagbare aandoeningen in Nederland in 2023. [Sexually transmitted infections in the Netherlands in 2023]. Amsterdam: National Institute for Public Health and the Environment (RIVM); 2024.Dutch. Available from: https://www.rivm.nl/publicaties/sexually-transmitted-infections-in-netherlands-in-2023
  11. Theodosiou AA, Jones CE, Read RC, Bogaert D. Microbiotoxicity: antibiotic usage and its unintended harm to the microbiome. Curr Opin Infect Dis. 2023;36(5):371-8.  https://doi.org/10.1097/QCO.0000000000000945  PMID: 37466039 
  12. Centers for Disease Control and Prevention (CDC). Chlamydial Infections. Atlanta: CDC. [Accessed: 18 Jul 2025]. Available from: https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm
  13. Centers for Disease Control and Prevention (CDC). Gonococcal Infections Among Adolescents and Adults. Atlanta: CDC. [Accessed: 18 Jul 2025]. Available from: https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm
  14. Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI Management Guidelines for Use in Primary Care: Chlamydia. Sydney: ASHM; 2023. [Accessed: 5 Jul 2025]. Available from: https://sti.guidelines.org.au/sexually-transmissible-infections/chlamydia/
  15. Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI Management Guidelines for Use in Primary Care: Gonorrhoea. Sydney: ASHM; 2023. [Accessed: 5 Jul 2025]. Available from: https://sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea/
  16. International Union against Sexually Transmitted Infections (IUSTI). IUSTI Treatment guidelines. Partner Management (2024). Droitwich: IUSTI. [Accessed: 3 Sep 2025]. Available from: https://files.magicapp.org/guideline/7f8e15c7-071b-45a8-9b33-6fd65f31da17/published_guideline_8829-1_1.pdf
  17. White JA, Dukers-Muijrers NH, Hoebe CJ, Kenyon CR, Dc Ross J, Unemo M. 2025 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2025;36(6):434-49.  https://doi.org/10.1177/09564624251323678  PMID: 40037375 
  18. National Institute for Public Health and the Environment (RIVM). Gonorroe. LCI-richtlijn. [ Gonorrhoea. LCI guideline]. Bilthoven: RIVM. [Accessed: 18 Jul 2025]. Dutch. Available from: https://lci.rivm.nl/richtlijnen/gonorroe
  19. National Institute for Public Health and the Environment (RIVM). Chlamydia trachomatis en lymphogranuloma venereum. LCI-richtlijn. [Chlamydia trachomatis and lymphogranuloma venereum. LCI guidelines]. Bilthoven: RIVM. [Accessed: 24 Feb 2025]. Dutch. Available from: https://lci.rivm.nl/richtlijnen/chlamydia-trachomatis-en-lymfogranuloma-venereum
  20. Teker B, Schim van der Loeff MF, Boyd A, Hoornenborg E, Stam AJ, de Vries HJC, et al. Increase in Neisseria gonorrhoeae infections after ending COVID-19 lockdown measures in Amsterdam, the Netherlands. Sex Transm Infect. 2025;101(3):152-9.  https://doi.org/10.1136/sextrans-2024-056276  PMID: 39643436 
  21. Shover CL, Beymer MR, Unger EM, Javanbakht M, Bolan RK. Accuracy of Presumptive Gonorrhea Treatment for Gay, Bisexual, and Other Men Who Have Sex with Men: Results from a Large Sexual Health Clinic in Los Angeles, California. LGBT Health. 2018;5(2):139-44.  https://doi.org/10.1089/lgbt.2017.0115  PMID: 29493405 
  22. Pugsley RA, Peterman TA. Presumptive and Follow-up Treatment for Gonorrhea and Chlamydia Among Patients Attending Public Health Department Clinics in Virginia, 2016. Sex Transm Dis. 2019;46(3):199-205.  https://doi.org/10.1097/OLQ.0000000000000922  PMID: 30742592 
  23. Rowlinson E, Golden MR, Berzkalns A, Thibault C, Barbee LA. Epidemiologic Treatment for Contacts to Neisseria gonorrhoeae and Chlamydia trachomatis Infection in Sexually Transmitted Disease Clinic Patients in Seattle, WA; 1994 to 2018. Sex Transm Dis. 2020;47(10):665-71.  https://doi.org/10.1097/OLQ.0000000000001234  PMID: 32649579 
  24. Ng S, Thanthree DKJ, Chen MY, Fairley CK, Bradshaw CS, Ong JJ, et al., editors. Management of gonorrhoea contacts: evaluation of a change from universal to selective treatment. International Union against Sexually Transmitted Infections (IUSTI) World Congress 2024; September 2024; Sydney, Australia. Abstract. Available from: https://connectsci.au/sh/article/21/4/SHv21n4abs/159/Abstracts-from-the-25th-IUSTI-World-Congress
  25. Menon-Johansson AS, McNaught F, Mandalia S, Sullivan AK. Texting decreases the time to treatment for genital Chlamydia trachomatis infection. Sex Transm Infect. 2006;82(1):49-51.  https://doi.org/10.1136/sti.2004.014381  PMID: 16461603 
  26. de Vries DC, Jongen VW, Zimmermann HML, Davidovich U, Hoornenborg E, de Vries HJC. Sexual Distancing During 5 Periods Around and During the COVID-19 Pandemic, Amsterdam, the Netherlands. Sex Transm Dis. 2024;51(1):72-80.  https://doi.org/10.1097/OLQ.0000000000001888  PMID: 37889934 
  27. de Greeff SC, Kolwijck E, Schoffelen AF. NethMap 2024. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2023. Bilthoven: National Institute for Public Health and the Environment (RIVM). [Accessed: 18 Nov 2024]. Available from: https://www.rivm.nl/publicaties/nethmap-2023-consumption-of-antimicrobial-agents-and-antimicrobial-resistance
  28. European Medicines Agency (EMA). Multi-agency report highlights importance of reducing antibiotic use. Amsterdam: EMA. [Accessed: 29 Jan 2025]. Available from: https://www.ema.europa.eu/en/news/multi-agency-report-highlights-importance-reducing-antibiotic-use
  29. Kenyon C, Herrmann B, Hughes G, de Vries HJC. Management of asymptomatic sexually transmitted infections in Europe: towards a differentiated, evidence-based approach. Lancet Reg Health Eur. 2023;34:100743.  https://doi.org/10.1016/j.lanepe.2023.100743  PMID: 37927435 
  30. Alexiou ZW, Hoenderboom BM, Hoebe CJPA, Dukers-Muijrers NHTM, Götz HM, van der Sande MAB, et al. Reproductive tract complication risks following Chlamydia trachomatis infections: a long-term prospective cohort study from 2008 to 2022. Lancet Reg Health Eur. 2024;45:101027.  https://doi.org/10.1016/j.lanepe.2024.101027  PMID: 39247903 
  31. van Liere GAFS, Hoebe CJPA, Dirks JA, Wolffs PF, Dukers-Muijrers NHTM. Spontaneous clearance of urogenital, anorectal and oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women, MSM and heterosexual men visiting the STI clinic: a prospective cohort study. Sex Transm Infect. 2019;95(7):505-10.  https://doi.org/10.1136/sextrans-2018-053825  PMID: 30858330 
  32. Teker B, de Vries H, Heijman T, van Dam A, Schim van der Loeff M, Jongen VW. Spontaneous clearance of asymptomatic anogenital and pharyngeal Neisseria gonorrhoeae: a secondary analysis from the NABOGO trial. Sex Transm Infect. 2023;99(4):219-25. PMID: 35820778 
  33. Mensforth S, Ayinde OC, Ross J. Spontaneous clearance of genital and extragenital Neisseria gonorrhoeae: data from GToG. Sex Transm Infect. 2020;96(8):556-61.  https://doi.org/10.1136/sextrans-2020-054500  PMID: 32732336 
  34. van Rooijen MS, van der Loeff MF, Morré SA, van Dam AP, Speksnijder AGCL, de Vries HJC. Spontaneous pharyngeal Chlamydia trachomatis RNA clearance. A cross-sectional study followed by a cohort study of untreated STI clinic patients in Amsterdam, The Netherlands. Sex Transm Infect. 2015;91(3):157-64.  https://doi.org/10.1136/sextrans-2014-051633  PMID: 25237127 
  35. de la Court F, Boyd A, Coyer L, van den Elshout M, de Vries HJC, Matser A, et al. The impact of COVID-19-related restrictions in 2020 on sexual healthcare use, pre-exposure prophylaxis use, and sexually transmitted infection incidence among men who have sex with men in Amsterdam, the Netherlands. HIV Med. 2023;24(2):212-23.  https://doi.org/10.1111/hiv.13374  PMID: 36226479 
  36. Teker B, Hoornenborg E, Schim van der Loeff MF, Boyd A, Heijne JC, Prins M, et al. Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024. Euro Surveill. 2025;30(26):2400707.  https://doi.org/10.2807/1560-7917.ES.2025.30.26.2400707  PMID: 40613130 
  37. Soa Aids Nederland. Landelijke werkgroep doxyPEP. Nederlandse stellingname doxyPEP jan 2025. [National doxyPEP Working Group. Dutch position statement on doxyPEP, January 2025]. Amsterdam: Soa Aids Nederland; 2025. Dutch. Available from: https://www.soaaids.nl/files/2026-01/Nederlandse%20stellingname%20doxyPEP%20definitief%20dec%202025-%20red%20.pdf
  38. Matser AHB, de Vries HJC, Hoornenborg E, Prins M, Davidovich U. What do men who have sex with men think of the use of antibiotics as pre- and post-exposure prophylaxis to prevent sexually transmitted infections? medRxiv. 2023
Evaluating a new partner management strategy for bacterial sexually transmitted infections after a change in 2020 in Amsterdam, the Netherlands, 2017 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Buhari+Teker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Teker Buhari</a>, <a href="/search?value1=Maarten+F+Schim+van+der+Loeff&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schim van der Loeff Maarten F</a>, <a href="/search?value1=Lois+Deden&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Deden Lois</a>, <a href="/search?value1=Jason+Schouten&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schouten Jason</a>, <a href="/search?value1=Elske+Hoornenborg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoornenborg Elske</a>, <a href="/search?value1=Vita+W+Jongen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jongen Vita W</a>, <a href="/search?value1=Henry+JC+de+Vries&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Vries Henry JC</a></span>. Evaluating a new partner management strategy for bacterial sexually transmitted infections after a change in 2020 in Amsterdam, the Netherlands, 2017 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(22):pii=2500754. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.22.2500754" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.22.2500754</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 26 Sept 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 05 Feb 2026 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.22.2500754
/content/10.2807/1560-7917.ES.2026.31.22.2500754
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error